Defective	O
binding	O
and	O
function	O
of	O
1	B-protein
,	I-protein
25-dihydroxyvitamin	I-protein
D3	I-protein
receptors	I-protein
in	O
peripheral	B-cell_type
mononuclear	I-cell_type
cells	I-cell_type
of	O
patients	O
with	O
end-organ	O
resistance	O
to	O
1	O
,	O
25-dihydroxyvitamin	O
D	O
.	O

Lectin-induced	O
DNA	O
synthesis	O
by	O
peripheral	B-cell_type
mononuclear	I-cell_type
cells	I-cell_type
from	O
17	O
normal	O
donors	O
was	O
inhibited	O
(	O
40-60	O
%	O
)	O
by	O
1	O
,	O
25-dihydroxyvitamin	O
D3	O
(	O
1	O
,	O
25	O
[	O
OH	O
]	O
2D3	O
)	O
at	O
physiological	O
concentrations	O
(	O
10	O
(	O
-10	O
)	O
-10	O
(	O
-9	O
)	O
M	O
)	O
.	O

The	O
lymphocytes	B-cell_type
acquire	O
specific	O
receptors	O
for	O
1	O
,	O
25	O
(	O
OH	O
)	O
2D3	O
upon	O
activation	O
by	O
the	O
lectins	B-protein
.	O

This	O
process	O
precedes	O
the	O
inhibitory	O
effect	O
of	O
1	O
,	O
25	O
(	O
OH	O
)	O
2D3	O
.	O

We	O
studied	O
lymphocytes	B-cell_type
from	O
six	O
patients	O
from	O
four	O
different	O
kindreds	O
with	O
the	O
syndrome	O
of	O
hereditary	O
end-organ	O
resistance	O
to	O
1	O
,	O
25	O
(	O
OH	O
)	O
2D	O
(	O
the	O
so-called	O
vitamin	O
D-dependent	O
rickets	O
type	O
II	O
)	O
.	O

In	O
five	O
patients	O
(	O
three	O
kindreds	O
)	O
peripheral	B-cell_type
blood	I-cell_type
mononuclear	I-cell_type
cells	I-cell_type
did	O
not	O
acquire	O
receptors	O
for	O
1	O
,	O
25	O
(	O
OH	O
)	O
2D3	O
upon	O
phytohemagglutinin-induced	O
activation	O
.	O

Moreover	O
,	O
in	O
contrast	O
to	O
normal	B-cell_type
lymphocytes	I-cell_type
,	O
the	O
mitogenic	O
stimulation	O
of	O
these	O
patients	O
'	O
lymphocytes	B-cell_type
by	O
phytohemagglutinin	B-protein
and	O
concanavalin	O
A	O
was	O
not	O
inhibited	O
by	O
1	O
,	O
25	O
(	O
OH	O
)	O
2D3	O
.	O

Activated	O
lymphocytes	B-cell_type
of	O
the	O
sixth	O
patient	O
from	O
a	O
fourth	O
kindred	O
exhibited	O
normal	O
binding	O
of	O
[	O
3H	O
]	O
1	O
,	O
25	O
(	O
OH	O
)	O
2D3	O
but	O
the	O
hormone	O
failed	O
to	O
inhibit	O
the	O
mitogenic	O
stimulation	O
.	O

A	O
similar	O
pattern	O
of	O
the	O
vitamin	O
D	O
effector	O
system	O
was	O
previously	O
observed	O
in	O
fibroblasts	O
cultured	O
from	O
skin	O
biopsies	O
of	O
the	O
same	O
group	O
of	O
patients	O
.	O

The	O
conclusions	O
from	O
these	O
findings	O
are	O
:	O
(	O
a	O
)	O
the	O
inhibition	O
of	O
mitogenic	O
stimulation	O
by	O
1	O
,	O
25	O
(	O
OH	O
)	O
2D3	O
is	O
mediated	O
by	O
specific	B-protein
functional	I-protein
receptors	I-protein
to	O
the	O
hormone	O
;	O
and	O
(	O
b	O
)	O
the	O
receptors	O
for	O
1	O
,	O
25	O
(	O
OH	O
)	O
2D3	O
in	O
mononuclear	B-cell_type
cells	I-cell_type
are	O
probably	O
controlled	O
genetically	O
by	O
the	O
same	O
mechanisms	O
as	O
the	O
effector	O
system	O
in	O
well-characterized	O
target	O
organs	O
of	O
the	O
hormone	O
,	O
such	O
as	O
intestine	O
and	O
kidney	O
.	O

Defective	NULL
Binding	NULL
and	NULL
Function	NULL
of	NULL
1,25-Dihydroxyvitamin	NULL
D	NULL
;	NULL
Receptors	NULL
in	NULL
Peripheral	NULL
Mononuciear	NULL
Cells	NULL
of	NULL
Patients	NULL
with	NULL
End-organ	NULL
Resistance	NULL
to	NULL
1,25-Dihydroxyvitamin	NULL
D	NULL
Ruth	NULL
Koren	NULL
,	NULL
Amiram	NULL
Ravid	NULL
,	NULL
Uri	NULL
A.	NULL
Liberman	NULL
,	NULL
Zeev	NULL
Hochberg	NULL
,	NULL
Yosef	NULL
Weisman	NULL
,	NULL
and	NULL
Abraham	NULL
Novogrodsky	NULL
Metabolic	NULL
Unit	NULL
and	NULL
Rogoff-Wellcome	NULL
Medical	NULL
Research	NULL
Institute	NULL
,	NULL
Beilinson	NULL
Medical	NULL
Center	NULL
,	NULL
Petah-Tikva	NULL
,	NULL
Israel	NULL
;	NULL
Department	NULL
of	NULL
Pediatrics	NULL
,	NULL
Rambam	NULL
Medical	NULL
Center	NULL
,	NULL
Haifa	NULL
,	NULL
Israel	NULL
;	NULL
and	NULL
Bone	NULL
Disease	NULL
Unit	NULL
,	NULL
Tel-Aviv	NULL
Medical	NULL
Center	NULL
,	NULL
Tel-Aviv	NULL
,	NULL
Israel	NULL
Abstract	NULL
Lectin-induced	NULL
DNA	NULL
synthesis	NULL
by	NULL
peripheral	NULL
mononuclear	NULL
cells	NULL
from	NULL
17	NULL
normal	NULL
donors	NULL
was	NULL
inhibited	NULL
(	NULL
40-60	NULL
%	NULL
)	NULL
by	NULL
1,25-dihydroxyvitamin	NULL
D	NULL
;	NULL
,	NULL
(	NULL
1,25	NULL
[	NULL
OH	NULL
}	NULL
;	NULL
D	NULL
;	NULL
)	NULL
at	NULL
physiological	NULL
concentrations	NULL
(	NULL
10-	NULL
``	NULL
°-10~	NULL
M	NULL
)	NULL
.	NULL

The	NULL
lymphocytes	NULL
acquire	NULL
specific	NULL
receptors	NULL
for	NULL
1,25	NULL
(	NULL
OH	NULL
)	NULL
;	NULL
D	NULL
;	NULL
,	NULL
upon	NULL
activation	NULL
by	NULL
the	NULL
lectins	NULL
.	NULL

This	NULL
process	NULL
precedes	NULL
the	NULL
inhibitory	NULL
effect	NULL
of	NULL
1,25	NULL
(	NULL
OH	NULL
)	NULL
;	NULL
D	NULL
;	NULL
.	NULL

We	NULL
studied	NULL
lymphocytes	NULL
from	NULL
six	NULL
patients	NULL
from	NULL
four	NULL
different	NULL
kindreds	NULL
with	NULL
the	NULL
syndrome	NULL
of	NULL
hereditary	NULL
end-organ	NULL
resistance	NULL
to	NULL
1,25	NULL
(	NULL
OH	NULL
)	NULL
;	NULL
D	NULL
(	NULL
the	NULL
so-called	NULL
vitamin	NULL
D-dependent	NULL
rickets	NULL
type	NULL
II	NULL
)	NULL
.	NULL

In	NULL
five	NULL
patients	NULL
(	NULL
three	NULL
kindreds	NULL
)	NULL
peripheral	NULL
blood	NULL
mononuclear	NULL
cells	NULL
did	NULL
not	NULL
acquire	NULL
receptors	NULL
for	NULL
1,25	NULL
(	NULL
OH	NULL
)	NULL
;	NULL
D	NULL
;	NULL
,	NULL
upon	NULL
phytohemagglutinin-in-duced	NULL
activation	NULL
.	NULL

Moreover	NULL
,	NULL
in	NULL
contrast	NULL
to	NULL
normal	NULL
lymphocytes	NULL
,	NULL
the	NULL
mitogenic	NULL
stimulation	NULL
of	NULL
these	NULL
patients	NULL
'	NULL
lymphocytes	NULL
by	NULL
phytohemagglutinin	NULL
and	NULL
concanavalin	NULL
A	NULL
was	NULL
not	NULL
inhibited	NULL
by	NULL
1,25	NULL
(	NULL
OH	NULL
)	NULL
;	NULL
D	NULL
;	NULL
.	NULL

Activated	NULL
lymphocytes	NULL
of	NULL
the	NULL
sixth	NULL
patient	NULL
from	NULL
a	NULL
fourth	NULL
kindred	NULL
exhibited	NULL
normal	NULL
binding	NULL
of	NULL
PH	NULL
]	NULL
1,25	NULL
(	NULL
OH	NULL
)	NULL
:	NULL
D	NULL
;	NULL
but	NULL
the	NULL
hormone	NULL
failed	NULL
to	NULL
inhibit	NULL
the	NULL
mitogenic	NULL
stimulation	NULL
.	NULL

A	NULL
similar	NULL
pattern	NULL
of	NULL
the	NULL
vitamin	NULL
D	NULL
effector	NULL
system	NULL
was	NULL
previously	NULL
observed	NULL
in	NULL
fibroblasts	NULL
cultured	NULL
from	NULL
skin	NULL
biopsies	NULL
of	NULL
the	NULL
same	NULL
group	NULL
of	NULL
patients	NULL
.	NULL

The	NULL
conclusions	NULL
from	NULL
these	NULL
findings	NULL
are	NULL
:	NULL
(	NULL
a	NULL
)	NULL
the	NULL
inhibition	NULL
of	NULL
mitogenic	NULL
stimulation	NULL
by	NULL
1,25	NULL
(	NULL
OH	NULL
)	NULL
;	NULL
D	NULL
;	NULL
is	NULL
mediated	NULL
by	NULL
specific	NULL
functional	NULL
receptors	NULL
to	NULL
the	NULL
hormone	NULL
;	NULL
and	NULL
(	NULL
5	NULL
)	NULL
the	NULL
receptors	NULL
for	NULL
1,25	NULL
(	NULL
OH	NULL
)	NULL
;	NULL
D	NULL
;	NULL
in	NULL
mononuclear	NULL
cells	NULL
are	NULL
probably	NULL
controlled	NULL
genetically	NULL
by	NULL
the	NULL
same	NULL
mechanisms	NULL
as	NULL
the	NULL
effector	NULL
system	NULL
in	NULL
well-characterized	NULL
target	NULL
organs	NULL
of	NULL
the	NULL
hormone	NULL
,	NULL
such	NULL
as	NULL
intestine	NULL
and	NULL
kidney	NULL
.	NULL

Introduction	NULL
1,25-dihydroxyvitamin	NULL
D	NULL
(	NULL
1,25	NULL
[	NULL
OH	NULL
]	NULL
;	NULL
D	NULL
)	NULL
'	NULL
is	NULL
the	NULL
most	NULL
biologically	NULL
active	NULL
natural	NULL
metabolite	NULL
of	NULL
vitamin	NULL
D.	NULL
The	NULL
target	NULL
of	NULL
1,25	NULL
(	NULL
OH	NULL
)	NULL
;	NULL
D	NULL
,	NULL
like	NULL
that	NULL
of	NULL
other	NULL
steroidal	NULL
hormones	NULL
,	NULL
is	NULL
the	NULL
nucleus	NULL
of	NULL
the	NULL
responding	NULL
cells	NULL
.	NULL

1,25	NULL
(	NULL
OH	NULL
)	NULL
;	NULL
D	NULL
manifests	NULL
its	NULL
effect	NULL
by	NULL
a	NULL
multistep	NULL
process	NULL
resulting	NULL
in	NULL
the	NULL
induction	NULL
of	NULL
specific	NULL
messenger	NULL
RNA	NULL
and	NULL
protein	NULL
synthesis	NULL
(	NULL
1	NULL
,	NULL
2	NULL
)	NULL
.	NULL

Recent	NULL
developments	NULL
in	NULL
the	NULL
field	NULL
of	NULL
vitamin	NULL
D	NULL
endocrinology	NULL
indicate	NULL
that	NULL
receptors	NULL
for	NULL
1,25	NULL
(	NULL
OH	NULL
)	NULL
;	NULL
D	NULL
are	NULL
present	NULL
not	NULL
only	NULL
in	NULL
the	NULL
classical	NULL
target	NULL
organs	NULL
Address	NULL
correspondence	NULL
to	NULL
Dr.	NULL
Liberman	NULL
,	NULL
Metabolic	NULL
Disease	NULL
Unit	NULL
,	NULL
Beilinson	NULL
Medical	NULL
Center	NULL
,	NULL
Petah-Tikva	NULL
,	NULL
49100	NULL
Israel	NULL
.	NULL

Received	NULL
for	NULL
publication	NULL
14	NULL
January	NULL
1985.	NULL
.	NULL

Abbreviations	NULL
used	NULL
in	NULL
this	NULL
paper	NULL
:	NULL
Con	NULL
A	NULL
,	NULL
concanavalin	NULL
A	NULL
;	NULL
1,25	NULL
(	NULL
OH	NULL
)	NULL
;	NULL
D	NULL
,	NULL
1,25-dihydroxyvitamin	NULL
D	NULL
;	NULL
1,25	NULL
(	NULL
OH	NULL
)	NULL
;	NULL
D	NULL
;	NULL
,	NULL
1,25-dihydroxyvitamin	NULL
D	NULL
;	NULL
;	NULL
DDII	NULL
,	NULL
vitamin	NULL
D-dependent	NULL
rickets	NULL
type	NULL
II	NULL
;	NULL
PHA	NULL
,	NULL
phytohemagglutinin	NULL
.	NULL

J.	NULL
Clin	NULL
.	NULL

Invest	NULL
.	NULL

©	NULL
The	NULL
American	NULL
Society	NULL
for	NULL
Clinical	NULL
Investigation	NULL
,	NULL
Inc.	NULL
0021-9738/85/11/2012/04	NULL
$	NULL
1.00	NULL
Volume	NULL
76	NULL
,	NULL
November	NULL
1985	NULL
,	NULL
2012-2015	NULL
2012	NULL
-	NULL
Koren	NULL
,	NULL
Ravid	NULL
,	NULL
Liberman	NULL
,	NULL
Hochberg	NULL
,	NULL
Weisman	NULL
,	NULL
and	NULL
Novogrodsky	NULL
of	NULL
vitamin	NULL
D	NULL
,	NULL
the	NULL
intestine	NULL
,	NULL
bone	NULL
,	NULL
and	NULL
kidney	NULL
,	NULL
but	NULL
also	NULL
in	NULL
other	NULL
organs	NULL
including	NULL
cellular	NULL
components	NULL
of	NULL
the	NULL
immune	NULL
system	NULL
(	NULL
3	NULL
,	NULL
4	NULL
)	NULL
.	NULL

Normal	NULL
human	NULL
resting	NULL
T	NULL
and	NULL
B	NULL
lymphocytes	NULL
do	NULL
not	NULL
contain	NULL
receptors	NULL
for	NULL
1,2	NULL
5	NULL
(	NULL
OH	NULL
)	NULL
;	NULL
D	NULL
;	NULL
.	NULL

However	NULL
,	NULL
they	NULL
acquire	NULL
such	NULL
receptors	NULL
upon	NULL
lectin-induced	NULL
stimulation	NULL
or	NULL
transformation	NULL
with	NULL
Epstein-Barr	NULL
virus	NULL
(	NULL
5	NULL
,	NULL
6	NULL
)	NULL
.	NULL

The	NULL
receptors	NULL
can	NULL
be	NULL
detected	NULL
24	NULL
h	NULL
after	NULL
lectin	NULL
treatment	NULL
(	NULL
6	NULL
)	NULL
.	NULL

[	NULL
}	NULL
H	NULL
]	NULL
Thymidine	NULL
incorporation	NULL
into	NULL
DNA	NULL
of	NULL
stimulated	NULL
peripheral	NULL
blood	NULL
T	NULL
lymphocytes	NULL
is	NULL
inhibited	NULL
by	NULL
1,2	NULL
5	NULL
(	NULL
OH	NULL
)	NULL
;	NULL
D	NULL
;	NULL
at	NULL
physiological	NULL
concentrations	NULL
(	NULL
7	NULL
)	NULL
.	NULL

We	NULL
have	NULL
demonstrated	NULL
the	NULL
presence	NULL
of	NULL
high	NULL
affinity	NULL
receptors	NULL
for	NULL
1,25	NULL
(	NULL
OH	NULL
)	NULL
;	NULL
D	NULL
;	NULL
in	NULL
medullary	NULL
mouse	NULL
thymocytes	NULL
and	NULL
their	NULL
absence	NULL
from	NULL
cortical	NULL
thymocytes	NULL
.	NULL

Concomitantly	NULL
,	NULL
we	NULL
have	NULL
found	NULL
that	NULL
1,25	NULL
(	NULL
OH	NULL
)	NULL
;	NULL
D	NULL
;	NULL
inhibits	NULL
the	NULL
mitogenic	NULL
stimulation	NULL
of	NULL
the	NULL
medullary	NULL
cells	NULL
but	NULL
has	NULL
no	NULL
effect	NULL
on	NULL
the	NULL
stimulation	NULL
of	NULL
the	NULL
cortical	NULL
cell	NULL
subpopulation	NULL
(	NULL
8	NULL
)	NULL
.	NULL

These	NULL
data	NULL
suggest	NULL
that	NULL
the	NULL
inhibitory	NULL
effect	NULL
of	NULL
1,25	NULL
(	NULL
OH	NULL
)	NULL
;	NULL
D	NULL
;	NULL
on	NULL
lymphocyte	NULL
response	NULL
is	NULL
mediated	NULL
by	NULL
specific	NULL
receptors	NULL
.	NULL

Study	NULL
of	NULL
lymphocytes	NULL
from	NULL
patients	NULL
with	NULL
the	NULL
syndrome	NULL
of	NULL
end-organ	NULL
resistance	NULL
to	NULL
1,25	NULL
(	NULL
OH	NULL
)	NULL
;	NULL
D	NULL
(	NULL
the	NULL
so-called	NULL
vitamin	NULL
D-dependent	NULL
rickets	NULL
type	NULL
II	NULL
[	NULL
DDII	NULL
]	NULL
)	NULL
provides	NULL
an	NULL
unusual	NULL
opportunity	NULL
to	NULL
challenge	NULL
this	NULL
assumption	NULL
.	NULL

DDII	NULL
is	NULL
a	NULL
hereditary	NULL
auto-somal	NULL
recessive	NULL
syndrome	NULL
characterized	NULL
by	NULL
early	NULL
onset	NULL
rickets	NULL
,	NULL
hypocalcemia	NULL
,	NULL
secondary	NULL
hyperparathyroidism	NULL
,	NULL
and	NULL
elevated	NULL
serum	NULL
levels	NULL
of	NULL
1,25	NULL
(	NULL
OH	NULL
)	NULL
;	NULL
D	NULL
before	NULL
or	NULL
during	NULL
treatment	NULL
with	NULL
high	NULL
doses	NULL
of	NULL
various	NULL
vitamin	NULL
D	NULL
metabolites	NULL
.	NULL

In	NULL
more	NULL
than	NULL
50	NULL
%	NULL
of	NULL
these	NULL
patients	NULL
total	NULL
alopecia	NULL
is	NULL
an	NULL
additional	NULL
characteristic	NULL
feature	NULL
.	NULL

It	NULL
was	NULL
demonstrated	NULL
recently	NULL
that	NULL
fibroblasts	NULL
cultured	NULL
from	NULL
human	NULL
skin	NULL
biopsies	NULL
have	NULL
receptors	NULL
for	NULL
1,2	NULL
5	NULL
(	NULL
OH	NULL
)	NULL
;	NULL
D	NULL
;	NULL
,	NULL
the	NULL
characteristic	NULL
features	NULL
of	NULL
which	NULL
are	NULL
similar	NULL
if	NULL
not	NULL
identical	NULL
to	NULL
those	NULL
of	NULL
known	NULL
target	NULL
cells	NULL
for	NULL
the	NULL
hormone	NULL
(	NULL
9	NULL
)	NULL
.	NULL

Using	NULL
fibroblasts	NULL
cultured	NULL
from	NULL
skin	NULL
biopsies	NULL
of	NULL
these	NULL
patients	NULL
,	NULL
a	NULL
spectrum	NULL
of	NULL
defects	NULL
in	NULL
the	NULL
intracellular	NULL
receptor	NULL
mechanism	NULL
has	NULL
been	NULL
demonstrated	NULL
(	NULL
10	NULL
,	NULL
11	NULL
)	NULL
.	NULL

However	NULL
,	NULL
fibroblast	NULL
culture	NULL
is	NULL
a	NULL
costly	NULL
and	NULL
time-consuming	NULL
procedure	NULL
.	NULL

If	NULL
patients	NULL
with	NULL
DDII	NULL
have	NULL
a	NULL
universal	NULL
defect	NULL
in	NULL
1,25	NULL
(	NULL
OH	NULL
)	NULL
;	NULL
D	NULL
;	NULL
receptors	NULL
in	NULL
multiple	NULL
organs	NULL
,	NULL
such	NULL
a	NULL
defect	NULL
should	NULL
be	NULL
manifested	NULL
in	NULL
their	NULL
lymphocytes	NULL
as	NULL
well	NULL
.	NULL

In	NULL
this	NULL
report	NULL
we	NULL
demonstrated	NULL
that	NULL
peripheral	NULL
blood	NULL
lymphocytes	NULL
from	NULL
a	NULL
group	NULL
of	NULL
patients	NULL
with	NULL
DDII	NULL
do	NULL
not	NULL
acquire	NULL
receptors	NULL
for	NULL
1,25	NULL
(	NULL
OH	NULL
)	NULL
;	NULL
D	NULL
;	NULL
upon	NULL
mitogen	NULL
stimulation	NULL
.	NULL

Moreover	NULL
,	NULL
the	NULL
stimulation	NULL
of	NULL
these	NULL
lymphocytes	NULL
,	NULL
in	NULL
contrast	NULL
to	NULL
normal	NULL
lymphocytes	NULL
,	NULL
was	NULL
refractory	NULL
to	NULL
inhibition	NULL
by	NULL
1,25	NULL
(	NULL
OH	NULL
)	NULL
;	NULL
D	NULL
;	NULL
.	NULL

These	NULL
data	NULL
strongly	NULL
support	NULL
the	NULL
conclusion	NULL
that	NULL
inhibition	NULL
of	NULL
stimulation	NULL
by	NULL
1,25	NULL
(	NULL
OH	NULL
)	NULL
;	NULL
D	NULL
;	NULL
is	NULL
mediated	NULL
by	NULL
specific	NULL
receptors	NULL
for	NULL
the	NULL
hormone	NULL
and	NULL
that	NULL
peripheral	NULL
lymphocytes	NULL
may	NULL
serve	NULL
as	NULL
a	NULL
rapid	NULL
diagnostic	NULL
tool	NULL
for	NULL
DDIL	NULL
.	NULL

Methods	NULL
Subjects	NULL
.	NULL

This	NULL
study	NULL
included	NULL
six	NULL
patients	NULL
aged	NULL
3-22	NULL
yr	NULL
of	NULL
four	NULL
kindreds	NULL
:	NULL
Two	NULL
affected	NULL
siblings	NULL
in	NULL
kindreds	NULL
1	NULL
and	NULL
3	NULL
,	NULL
and	NULL
one	NULL
affected	NULL
patient	NULL
in	NULL
kindreds	NULL
2	NULL
and	NULL
4	NULL
.	NULL

The	NULL
patients	NULL
had	NULL
typical	NULL
clinical	NULL
and	NULL
biochemical	NULL
features	NULL
of	NULL
DDII	NULL
,	NULL
including	NULL
alopecia	NULL
.	NULL

Detailed	NULL
clinical	NULL
descriptions	NULL
of	NULL
the	NULL
patients	NULL
were	NULL
published	NULL
previously	NULL
(	NULL
11	NULL
,	NULL
12	NULL
)	NULL
.	NULL

No	NULL
measurable	NULL
cytosol	NULL
receptors	NULL
or	NULL
nuclear	NULL
uptake	NULL
of	NULL
[	NULL
'	NULL
H	NULL
]	NULL
1,25	NULL
(	NULL
OH	NULL
)	NULL
;	NULL
D	NULL
;	NULL
could	NULL
be	NULL
observed	NULL
in	NULL
studies	NULL
with	NULL
fibroblasts	NULL
cultured	NULL
from	NULL
skin	NULL
biopsies	NULL
of	NULL
kindreds	NULL
1-3	NULL
(	NULL
11	NULL
)	NULL
.	NULL

Normal	NULL
capacity	NULL
and	NULL
affinity	NULL
of	NULL
cytosol	NULL
receptors	NULL
and	NULL
nuclear	NULL
uptake	NULL
was	NULL
demonstrated	NULL
for	NULL
patient	NULL
No	NULL
.	NULL

4	NULL
(	NULL
10	NULL
)	NULL
.	NULL

Normal	NULL
donors	NULL
were	NULL
young	NULL
adults	NULL
except	NULL
for	NULL
one	NULL
10-yr-old	NULL
girl	NULL
(	NULL
normal	NULL
2	NULL
)	NULL
.	NULL

Materials	NULL
.	NULL

Purified	NULL
phytohemagglutinin	NULL
(	NULL
PHA	NULL
)	NULL
was	NULL
obtained	NULL
from	NULL
Wellcome	NULL
Research	NULL
Laboratories	NULL
,	NULL
Beckenham	NULL
,	NULL
Kent	NULL
,	NULL
England	NULL
;	NULL
concanavalin	NULL
A	NULL
(	NULL
Con	NULL
A	NULL
)	NULL
,	NULL
twice	NULL
chrystallized	NULL
,	NULL
from	NULL
Miles-Yeda	NULL
,	NULL
Rehovot	NULL
,	NULL
Israel	NULL
;	NULL
Ficoll-Hypaque	NULL
from	NULL
Pharmacia	NULL
Fine	NULL
Chemicals	NULL
,	NULL
Uppsala	NULL
,	NULL
Sweden	NULL
;	NULL
1,25	NULL
(	NULL
OH	NULL
)	NULL
;	NULL
D	NULL
;	NULL
from	NULL
Hoffmann-LaRoche	NULL
Inc.	NULL
,	NULL
Nutley	NULL
,	NULL
NJ	NULL
(	NULL
a	NULL
gift	NULL
from	NULL
Dr.	NULL
M.	NULL
Uskokovic	NULL
)	NULL
;	NULL
aprotinin	NULL
from	NULL
Bayer	NULL
,	NULL
Leverkusen-Bayerwerk	NULL
,	NULL
Germany	NULL
;	NULL
and	NULL
Bio-Gel	NULL
HTP	NULL
hydroxylapatite	NULL
was	NULL
from	NULL
Bio-Rad	NULL
Laboratories	NULL
,	NULL
Richmond	NULL
,	NULL
CA	NULL
.	NULL

1,25	NULL
(	NULL
23,24	NULL
(	NULL
n	NULL
}	NULL
H	NULL
]	NULL
(	NULL
OH	NULL
)	NULL
;	NULL
D	NULL
;	NULL
was	NULL
from	NULL
New	NULL
England	NULL
Nu-clear	NULL
,	NULL
Boston	NULL
,	NULL
MA	NULL
(	NULL
160	NULL
Ci/mmol	NULL
)	NULL
;	NULL
[	NULL
methy/-	NULL
``	NULL
H	NULL
]	NULL
thymidine	NULL
was	NULL
from	NULL
Nuclear	NULL
Research	NULL
Center	NULL
Negev	NULL
,	NULL
Beer-Sheva	NULL
,	NULL
Israel	NULL
,	NULL
(	NULL
2	NULL
Ci/mmol	NULL
)	NULL
;	NULL
and	NULL
tissue	NULL
~	NULL
culture	NULL
media	NULL
were	NULL
obtained	NULL
from	NULL
Biological	NULL
Industries	NULL
,	NULL
Beth-Haemek	NULL
,	NULL
Israel	NULL
.	NULL

Lymphocyte	NULL
culture	NULL
.	NULL

Human	NULL
peripheral	NULL
blood	NULL
mononuclear	NULL
cells	NULL
were	NULL
obtained	NULL
from	NULL
20-ml	NULL
blood	NULL
samples	NULL
by	NULL
Ficoll-Hypaque	NULL
density	NULL
gradient	NULL
centrifugation	NULL
as	NULL
previously	NULL
described	NULL
(	NULL
13	NULL
)	NULL
.	NULL

Mononuclear	NULL
cells	NULL
(	NULL
1	NULL
x	NULL
10°/	NULL
ml	NULL
)	NULL
were	NULL
suspended	NULL
in	NULL
RPMI	NULL
1640	NULL
medium	NULL
containing	NULL
5	NULL
%	NULL
heat-inac-tivated	NULL
human	NULL
AB	NULL
serum	NULL
supplemented	NULL
with	NULL
penicillin	NULL
(	NULL
100	NULL
U/ml	NULL
)	NULL
and	NULL
streptomycin	NULL
(	NULL
100	NULL
ug/ml	NULL
)	NULL
.	NULL

Cells	NULL
were	NULL
incubated	NULL
at	NULL
37°C	NULL
in	NULL
a	NULL
humidified	NULL
5	NULL
%	NULL
CO	NULL
;	NULL
-95	NULL
%	NULL
air	NULL
atmosphere	NULL
in	NULL
0.2-ml	NULL
aliquots	NULL
in	NULL
flat-bottomed	NULL
Cooke	NULL
microtiter	NULL
plates	NULL
(	NULL
Nunc	NULL
,	NULL
Roskilde	NULL
,	NULL
Denmark	NULL
)	NULL
.	NULL

Con	NULL
A	NULL
(	NULL
10	NULL
PHA	NULL
(	NULL
1	NULL
g/ml	NULL
)	NULL
,	NULL
and	NULL
1,25	NULL
(	NULL
OH	NULL
)	NULL
;	NULL
D	NULL
;	NULL
(	NULL
10~°-10~°	NULL
M	NULL
)	NULL
were	NULL
added	NULL
at	NULL
zero	NULL
time	NULL
.	NULL

Cultures	NULL
were	NULL
incubated	NULL
for	NULL
68	NULL
h.	NULL
PH	NULL
]	NULL
Thymidine	NULL
(	NULL
1	NULL
uCi/well	NULL
)	NULL
was	NULL
added	NULL
4	NULL
h	NULL
before	NULL
harvesting	NULL
.	NULL

All	NULL
cultures	NULL
were	NULL
carried	NULL
out	NULL
in	NULL
triplicates	NULL
.	NULL

Binding	NULL
studies	NULL
.	NULL

Binding	NULL
of	NULL
[	NULL
PH	NULL
]	NULL
1,25	NULL
(	NULL
OH	NULL
)	NULL
;	NULL
D	NULL
;	NULL
to	NULL
receptors	NULL
in	NULL
mononuclear	NULL
cells	NULL
was	NULL
assayed	NULL
as	NULL
previously	NULL
described	NULL
(	NULL
8	NULL
,	NULL
10	NULL
)	NULL
.	NULL

Peripheral	NULL
blood	NULL
mononuclear	NULL
cells	NULL
(	NULL
1	NULL
X	NULL
10®/ml	NULL
)	NULL
were	NULL
incubated	NULL
with	NULL
PHA	NULL
(	NULL
1	NULL
pg/ml	NULL
)	NULL
under	NULL
the	NULL
same	NULL
culture	NULL
conditions	NULL
described	NULL
above	NULL
in	NULL
9-cm	NULL
tissue	NULL
culture	NULL
dishes	NULL
(	NULL
Nunc	NULL
)	NULL
,	NULL
15	NULL
ml/dish	NULL
.	NULL

Stimulated	NULL
cells	NULL
were	NULL
harvested	NULL
after	NULL
3	NULL
d	NULL
and	NULL
washed	NULL
3	NULL
times	NULL
with	NULL
ice	NULL
cold	NULL
phosphate-buffered	NULL
saline	NULL
.	NULL

All	NULL
further	NULL
procedures	NULL
were	NULL
performed	NULL
at	NULL
0O-4°C	NULL
.	NULL

Cells	NULL
were	NULL
suspended	NULL
in	NULL
a	NULL
high	NULL
KCl	NULL
buffer	NULL
(	NULL
10	NULL
mM	NULL
Tris-HCl	NULL
,	NULL
pH	NULL
7.4	NULL
;	NULL
300	NULL
mM	NULL
KCI	NULL
;	NULL
10	NULL
mM	NULL
sodium	NULL
mo-lybdate	NULL
;	NULL
1.5	NULL
mM	NULL
EDTA	NULL
;	NULL
1.0	NULL
mM	NULL
dithiothreitol	NULL
;	NULL
and	NULL
500	NULL
kallikrein	NULL
in-activator	NULL
U/ml	NULL
approtinin	NULL
)	NULL
.	NULL

The	NULL
suspension	NULL
was	NULL
sonicated	NULL
(	NULL
three	NULL
5-s	NULL
pulses	NULL
)	NULL
with	NULL
Heat-System-UlItrasonics	NULL
Cell	NULL
Disruptor	NULL
model	NULL
M-375	NULL
(	NULL
Ul-trasonic	NULL
Corp.	NULL
of	NULL
America	NULL
,	NULL
Hicksville	NULL
,	NULL
NY	NULL
)	NULL
set	NULL
at	NULL
gain	NULL
3	NULL
.	NULL

The	NULL
sonicate	NULL
was	NULL
centrifuged	NULL
at	NULL
100,000	NULL
g	NULL
for	NULL
60	NULL
min	NULL
.	NULL

The	NULL
supernatant	NULL
was	NULL
saved	NULL
and	NULL
will	NULL
be	NULL
referred	NULL
to	NULL
as	NULL
``	NULL
cytosol	NULL
.	NULL
``	NULL

Freshly	NULL
prepared	NULL
cytosols	NULL
were	NULL
incubated	NULL
with	NULL
1	NULL
nM	NULL
[	NULL
°H	NULL
]	NULL
1,25	NULL
(	NULL
OH	NULL
)	NULL
;	NULL
D	NULL
;	NULL
for	NULL
17	NULL
h	NULL
at	NULL
0°C	NULL
.	NULL

Bound	NULL
[	NULL
PH	NULL
]	NULL
1,25	NULL
(	NULL
OH	NULL
)	NULL
;	NULL
D	NULL
;	NULL
was	NULL
separated	NULL
from	NULL
free	NULL
hormone	NULL
by	NULL
the	NULL
hydroxylapatite	NULL
batch	NULL
separation	NULL
procedure	NULL
.	NULL

Nonspecific	NULL
binding	NULL
was	NULL
assessed	NULL
under	NULL
conditions	NULL
where	NULL
1,000-fold	NULL
excess	NULL
of	NULL
cold	NULL
hormone	NULL
was	NULL
present	NULL
in	NULL
the	NULL
binding	NULL
assay	NULL
.	NULL

Protein	NULL
was	NULL
determined	NULL
by	NULL
the	NULL
method	NULL
of	NULL
Lowry	NULL
et	NULL
al	NULL
.	NULL

(	NULL
14	NULL
)	NULL
.	NULL

Protein	NULL
concentrations	NULL
in	NULL
the	NULL
cytosols	NULL
were	NULL
between	NULL
1.2	NULL
and	NULL
2	NULL
mg/ml	NULL
.	NULL

All	NULL
binding	NULL
assays	NULL
were	NULL
performed	NULL
in	NULL
duplicates	NULL
.	NULL

Statistical	NULL
analysis	NULL
.	NULL

Data	NULL
of	NULL
[	NULL
H	NULL
]	NULL
thymidine	NULL
incorporation	NULL
are	NULL
presented	NULL
as	NULL
mean+SD	NULL
.	NULL

Statistical	NULL
analysis	NULL
was	NULL
carried	NULL
out	NULL
by	NULL
means	NULL
of	NULL
unpaired	NULL
/	NULL
test	NULL
.	NULL

Results	NULL
The	NULL
effect	NULL
of	NULL
1,25	NULL
(	NULL
OH	NULL
)	NULL
;	NULL
D	NULL
;	NULL
at	NULL
different	NULL
concentrations	NULL
on	NULL
Con	NULL
A-mediated	NULL
stimulation	NULL
of	NULL
mononuclear	NULL
cells	NULL
from	NULL
two	NULL
normal	NULL
volunteers	NULL
is	NULL
depicted	NULL
in	NULL
Table	NULL
I.	NULL
Inhibition	NULL
of	NULL
incorporation	NULL
into	NULL
stimulated	NULL
lymphocytes	NULL
is	NULL
observed	NULL
already	NULL
at	NULL
107°	NULL
M	NULL
1,25	NULL
(	NULL
OH	NULL
)	NULL
;	NULL
D	NULL
;	NULL
,	NULL
and	NULL
reaches	NULL
a	NULL
peak	NULL
at	NULL
107°	NULL
M	NULL
with	NULL
no	NULL
additional	NULL
change	NULL
at	NULL
concentrations	NULL
of	NULL
up	NULL
to	NULL
10~°	NULL
M.	NULL
Half	NULL
of	NULL
the	NULL
maximal	NULL
inhibition	NULL
is	NULL
achieved	NULL
at	NULL
a	NULL
concentration	NULL
of	NULL
1-2	NULL
xX	NULL
107°	NULL
M	NULL
1,25	NULL
(	NULL
OH	NULL
)	NULL
;	NULL
D	NULL
;	NULL
.	NULL

[	NULL
}	NULL
H	NULL
]	NULL
Thymidine	NULL
incorporation	NULL
into	NULL
Resistance	NULL
to	NULL
1,25-Dihydroxyvitamin	NULL
D	NULL
;	NULL
and	NULL
Lymphocyte	NULL
Mitogenesis	NULL
Table	NULL
I	NULL
.	NULL

Effect	NULL
of	NULL
1,25	NULL
(	NULL
OH	NULL
)	NULL
;	NULL
D	NULL
;	NULL
on	NULL
Con	NULL
A-induced	NULL
Stimulation	NULL
of	NULL
Mononuclear	NULL
Cells	NULL
from	NULL
Normal	NULL
Subjects	NULL
and	NULL
a	NULL
Patient	NULL
with	NULL
DDII*	NULL
[	NULL
'	NULL
H	NULL
]	NULL
Thymidine	NULL
incorporation	NULL
[	NULL
1,25	NULL
(	NULL
OH	NULL
)	NULL
;	NULL
D	NULL
;	NULL
)	NULL
Normal	NULL
4a	NULL
Normal	NULL
4b	NULL
Patient	NULL
4	NULL
cpm	NULL
cpm	NULL
cpm	NULL
None	NULL
42,400£7,500	NULL
66,900+5,000	NULL
78,300+12,400	NULL
10~	NULL
``	NULL
°	NULL
M	NULL
27,100+7,500	NULL
61,400+600	NULL
76,600+3,900	NULL
3	NULL
x	NULL
107°	NULL
M	NULL
19,800+5,600	NULL
51,000+9,500	NULL
74,100+6,400	NULL
10~°	NULL
M	NULL
£0,800+1,300	NULL
47,500+2,300	NULL
75,1700+2,300	NULL
107	NULL
M	NULL
13,200+1,900	NULL
47,500+900	NULL
95,700+14,600	NULL
107	NULL
M	NULL
10,300+1,900	NULL
45,200+600	NULL
84,900+20,100	NULL
107°	NULL
M	NULL
12,600+3,000	NULL
46,200+5,400	NULL
83,200+3,300	NULL
*	NULL
Mononuclear	NULL
cells	NULL
were	NULL
incubated	NULL
with	NULL
Con	NULL
A	NULL
(	NULL
10	NULL
ug/ml	NULL
)	NULL
and	NULL
different	NULL
concentrations	NULL
of	NULL
1,25	NULL
(	NULL
OH	NULL
)	NULL
;	NULL
D	NULL
;	NULL
for	NULL
72	NULL
h	NULL
as	NULL
described	NULL
in	NULL
Methods	NULL
.	NULL

Cells	NULL
were	NULL
pulsed	NULL
with	NULL
[	NULL
°HJthymidine	NULL
in	NULL
the	NULL
last	NULL
4	NULL
h	NULL
of	NULL
the	NULL
incubation	NULL
.	NULL

Data	NULL
are	NULL
presented	NULL
as	NULL
the	NULL
mean+SD	NULL
of	NULL
triplicate	NULL
cultures	NULL
.	NULL

Data	NULL
obtained	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
10~°-10~°	NULL
M	NULL
1,25	NULL
(	NULL
OH	NULL
)	NULL
;	NULL
D	NULL
;	NULL
were	NULL
pooled	NULL
and	NULL
compared	NULL
with	NULL
the	NULL
control	NULL
by	NULL
means	NULL
of	NULL
unpaired	NULL
?	NULL

test	NULL
.	NULL

The	NULL
inhibition	NULL
was	NULL
significant	NULL
(	NULL
P	NULL
<	NULL
0.001	NULL
)	NULL
for	NULL
the	NULL
normal	NULL
donors	NULL
.	NULL

The	NULL
slight	NULL
enhancement	NULL
observed	NULL
for	NULL
patient	NULL
4	NULL
is	NULL
of	NULL
no	NULL
statistical	NULL
significance	NULL
.	NULL

lymphocytes	NULL
obtained	NULL
from	NULL
17	NULL
healthy	NULL
subjects	NULL
and	NULL
incubated	NULL
with	NULL
Con	NULL
A	NULL
and	NULL
1	NULL
nM	NULL
1,25	NULL
(	NULL
OH	NULL
)	NULL
;	NULL
D	NULL
;	NULL
for	NULL
72	NULL
h	NULL
was	NULL
60+11.5	NULL
%	NULL
(	NULL
SE	NULL
)	NULL
of	NULL
the	NULL
control	NULL
value	NULL
.	NULL

For	NULL
every	NULL
normal	NULL
donor	NULL
the	NULL
inhibition	NULL
was	NULL
highly	NULL
significant	NULL
(	NULL
P	NULL
<	NULL
0.01	NULL
)	NULL
.	NULL

In	NULL
preliminary	NULL
experiments	NULL
,	NULL
performed	NULL
under	NULL
the	NULL
same	NULL
experimental	NULL
conditions	NULL
,	NULL
we	NULL
established	NULL
that	NULL
the	NULL
decrease	NULL
in	NULL
thymidine	NULL
incorporation	NULL
was	NULL
accompanied	NULL
by	NULL
a	NULL
decrease	NULL
in	NULL
cell	NULL
number	NULL
.	NULL

In	NULL
a	NULL
typical	NULL
experiment	NULL
cell	NULL
number	NULL
decreased	NULL
by	NULL
~40	NULL
%	NULL
.	NULL

When	NULL
the	NULL
cultures	NULL
were	NULL
pulsed	NULL
with	NULL
[	NULL
°H	NULL
]	NULL
thymidine	NULL
at	NULL
48	NULL
h	NULL
,	NULL
no	NULL
inhibitory	NULL
effect	NULL
by	NULL
1,25	NULL
(	NULL
OH	NULL
)	NULL
;	NULL
D	NULL
;	NULL
was	NULL
observed	NULL
.	NULL

It	NULL
should	NULL
be	NULL
noted	NULL
that	NULL
receptors	NULL
for	NULL
1,25	NULL
(	NULL
OH	NULL
)	NULL
;	NULL
D	NULL
can	NULL
be	NULL
detected	NULL
on	NULL
T	NULL
lymphocytes	NULL
24	NULL
h	NULL
after	NULL
lectin	NULL
treatment	NULL
(	NULL
6	NULL
)	NULL
,	NULL
and	NULL
thus	NULL
receptor	NULL
appearance	NULL
precedes	NULL
the	NULL
expression	NULL
of	NULL
inhibition	NULL
.	NULL

The	NULL
effect	NULL
of	NULL
1,25	NULL
(	NULL
OH	NULL
)	NULL
;	NULL
D	NULL
;	NULL
on	NULL
Con	NULL
A-induced	NULL
stimulation	NULL
of	NULL
mononuclear	NULL
cells	NULL
from	NULL
children	NULL
with	NULL
DDII	NULL
is	NULL
depicted	NULL
in	NULL
Fig	NULL
.	NULL

1	NULL
and	NULL
Table	NULL
I	NULL
.	NULL

Four	NULL
separate	NULL
experiments	NULL
were	NULL
carried	NULL
out	NULL
,	NULL
each	NULL
was	NULL
performed	NULL
on	NULL
cells	NULL
from	NULL
children	NULL
of	NULL
different	NULL
kindred	NULL
,	NULL
with	NULL
normal	NULL
donors	NULL
serving	NULL
as	NULL
controls	NULL
.	NULL

The	NULL
{	NULL
*H	NULL
]	NULL
thymidine	NULL
incorporation	NULL
into	NULL
Con	NULL
A-stimulated	NULL
lymphocytes	NULL
from	NULL
the	NULL
six	NULL
patients	NULL
was	NULL
essentially	NULL
refractory	NULL
to	NULL
inhibition	NULL
by	NULL
1,25	NULL
(	NULL
OH	NULL
)	NULL
;	NULL
D	NULL
;	NULL
.	NULL

The	NULL
deviations	NULL
from	NULL
control	NULL
values	NULL
never	NULL
reached	NULL
statistical	NULL
significance	NULL
.	NULL

In	NULL
contrast	NULL
,	NULL
1,25	NULL
(	NULL
OH	NULL
)	NULL
;	NULL
D	NULL
;	NULL
inhibited	NULL
the	NULL
mitogenic	NULL
response	NULL
of	NULL
lymphocytes	NULL
from	NULL
six	NULL
normal	NULL
subjects	NULL
that	NULL
served	NULL
as	NULL
controls	NULL
in	NULL
the	NULL
same	NULL
experiments	NULL
.	NULL

The	NULL
inhibition	NULL
was	NULL
dose-dependent	NULL
and	NULL
ranged	NULL
between	NULL
43	NULL
and	NULL
52	NULL
%	NULL
.	NULL

The	NULL
differences	NULL
between	NULL
the	NULL
hormone	NULL
effect	NULL
on	NULL
lymphocytes	NULL
from	NULL
patients	NULL
and	NULL
respective	NULL
normal	NULL
donors	NULL
were	NULL
highly	NULL
significant	NULL
(	NULL
P	NULL
<	NULL
0.001	NULL
)	NULL
(	NULL
Fig	NULL
.	NULL

1	NULL
and	NULL
Table	NULL
D	NULL
)	NULL
.	NULL

We	NULL
have	NULL
studied	NULL
the	NULL
binding	NULL
of	NULL
1,25	NULL
(	NULL
OH	NULL
)	NULL
;	NULL
D	NULL
;	NULL
to	NULL
mononuclear	NULL
cells	NULL
stimulated	NULL
by	NULL
PHA	NULL
.	NULL

The	NULL
cell	NULL
preparations	NULL
used	NULL
in	NULL
the	NULL
binding	NULL
experiments	NULL
were	NULL
the	NULL
same	NULL
as	NULL
in	NULL
the	NULL
stimulation-inhibition	NULL
experiments	NULL
shown	NULL
in	NULL
Fig	NULL
.	NULL

1	NULL
and	NULL
Table	NULL
I	NULL
.	NULL

In	NULL
the	NULL
binding	NULL
experiments	NULL
we	NULL
used	NULL
PHA-	NULL
rather	NULL
than	NULL
Con	NULL
A-stimulated	NULL
cells	NULL
,	NULL
since	NULL
PHA	NULL
was	NULL
more	NULL
effective	NULL
in	NULL
generation	NULL
of	NULL
receptors	NULL
for	NULL
1,25	NULL
(	NULL
OH	NULL
)	NULL
;	NULL
D	NULL
;	NULL
,	NULL
probably	NULL
due	NULL
to	NULL
its	NULL
higher	NULL
potency	NULL
as	NULL
a	NULL
mitogen	NULL
.	NULL

As	NULL
shown	NULL
in	NULL
Table	NULL
II	NULL
,	NULL
PHA	NULL
stimulation	NULL
of	NULL
lymphocytes	NULL
from	NULL
normal	NULL
donors	NULL
is	NULL
significantly	NULL
(	NULL
P	NULL
<	NULL
0.01	NULL
)	NULL
inhibited	NULL
by	NULL
1	NULL
nM	NULL
1,25	NULL
(	NULL
OH	NULL
)	NULL
;	NULL
D	NULL
;	NULL
,	NULL
similar	NULL
to	NULL
the	NULL
inhibition	NULL
of	NULL
Con	NULL
A	NULL
stimulation	NULL
2013	NULL
Kindred	NULL
1	NULL
Kindred	NULL
2	NULL
Kindred	NULL
3	NULL
Figure	NULL
1	NULL
.	NULL

Effect	NULL
of	NULL
1,25	NULL
(	NULL
OH	NULL
)	NULL
;	NULL
D	NULL
;	NULL
on	NULL
Con	NULL
A-in-	NULL
120	NULL
}	NULL
F	NULL
+	NULL
[	NULL
H	NULL
]	NULL
Thymidine	NULL
Incorporation	NULL
(	NULL
Zof	NULL
control	NULL
)	NULL
40	NULL
}	NULL
-	NULL
duced	NULL
stimulation	NULL
of	NULL
mononuclear	NULL
cells	NULL
from	NULL
normal	NULL
subjects	NULL
and	NULL
patients	NULL
with	NULL
DDII	NULL
.	NULL

Each	NULL
a	NULL
experiment	NULL
dealt	NULL
with	NULL
a	NULL
different	NULL
kindred	NULL
.	NULL

b	NULL
Kindred	NULL
1	NULL
:	NULL
patient	NULL
la	NULL
(	NULL
a	NULL
)	NULL
,	NULL
patient	NULL
1b	NULL
(	NULL
e	NULL
)	NULL
,	NULL
normal	NULL
1a	NULL
(	NULL
0	NULL
)	NULL
,	NULL
and	NULL
normal	NULL
1b	NULL
(	NULL
a	NULL
)	NULL
.	NULL

Kindred	NULL
2	NULL
:	NULL
patient	NULL
2	NULL
(	NULL
e	NULL
)	NULL
and	NULL
normal	NULL
2	NULL
(	NULL
0	NULL
)	NULL
.	NULL

Kindred	NULL
3	NULL
:	NULL
patient	NULL
3a	NULL
(	NULL
e	NULL
)	NULL
,	NULL
patient	NULL
3b	NULL
(	NULL
a	NULL
)	NULL
,	NULL
and	NULL
normal	NULL
3	NULL
(	NULL
0	NULL
)	NULL
.	NULL

Experimental	NULL
details	NULL
are	NULL
as	NULL
described	NULL
in	NULL
legend	NULL
to	NULL
Table	NULL
I	NULL
and	NULL
in	NULL
Methods	NULL
.	NULL

Data	NULL
are	NULL
presented	NULL
as	NULL
the	NULL
mean	NULL
of	NULL
triplicate	NULL
cultures	NULL
.	NULL

Data	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
10~°	NULL
and	NULL
107°	NULL
M	NULL
1,25	NULL
(	NULL
OH	NULL
)	NULL
;	NULL
D	NULL
;	NULL
were	NULL
pooled	NULL
and	NULL
compared	NULL
with	NULL
the	NULL
control	NULL
.	NULL

The	NULL
inhibition	NULL
of	NULL
thymidine	NULL
incorporation	NULL
for	NULL
all	NULL
normal	NULL
donors	NULL
was	NULL
statistically	NULL
significant	NULL
(	NULL
P	NULL
<	NULL
0.001	NULL
)	NULL
.	NULL

The	NULL
values	NULL
for	NULL
DDII	NULL
patients	NULL
were	NULL
not	NULL
significantly	NULL
lower	NULL
than	NULL
the	NULL
control	NULL
values	NULL
1,25	NULL
(	NULL
OH	NULL
)	NULL
D	NULL
;	NULL
,	NULL
[	NULL
M	NULL
]	NULL
described	NULL
above	NULL
.	NULL

On	NULL
the	NULL
other	NULL
hand	NULL
,	NULL
lymphocytes	NULL
from	NULL
patients	NULL
with	NULL
DDII	NULL
are	NULL
resistant	NULL
to	NULL
the	NULL
inhibitory	NULL
effect	NULL
of	NULL
the	NULL
hormone	NULL
.	NULL

Occasionally	NULL
,	NULL
we	NULL
observed	NULL
an	NULL
enhancing	NULL
effect	NULL
of	NULL
1,25	NULL
(	NULL
OH	NULL
)	NULL
;	NULL
D	NULL
;	NULL
on	NULL
PHA-induced	NULL
thymidine	NULL
incorporation	NULL
into	NULL
lymphocytes	NULL
from	NULL
these	NULL
patients	NULL
.	NULL

However	NULL
,	NULL
this	NULL
effect	NULL
was	NULL
not	NULL
dose-dependent	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
and	NULL
was	NULL
statistically	NULL
significant	NULL
only	NULL
in	NULL
two	NULL
out	NULL
of	NULL
the	NULL
six	NULL
patients	NULL
.	NULL

The	NULL
binding	NULL
of	NULL
[	NULL
°H	NULL
]	NULL
1,25	NULL
(	NULL
OH	NULL
)	NULL
;	NULL
D	NULL
;	NULL
to	NULL
cytosols	NULL
of	NULL
PHA-stimulated	NULL
mononuclear	NULL
cells	NULL
from	NULL
patients	NULL
with	NULL
DDII	NULL
(	NULL
P	NULL
>	NULL
0.05	NULL
)	NULL
.	NULL

The	NULL
differences	NULL
between	NULL
patients	NULL
and	NULL
respective	NULL
controls	NULL
were	NULL
statistically	NULL
significant	NULL
(	NULL
P	NULL
<	NULL
0.001	NULL
)	NULL
for	NULL
all	NULL
kindreds	NULL
.	NULL

is	NULL
practically	NULL
undetectable	NULL
in	NULL
patients	NULL
la	NULL
,	NULL
2	NULL
,	NULL
3a	NULL
,	NULL
and	NULL
3b	NULL
,	NULL
and	NULL
normal	NULL
in	NULL
patient	NULL
4	NULL
.	NULL

The	NULL
lack	NULL
of	NULL
binding	NULL
of	NULL
1,25	NULL
(	NULL
OH	NULL
)	NULL
;	NULL
D	NULL
;	NULL
to	NULL
lymphocytes	NULL
from	NULL
some	NULL
of	NULL
the	NULL
patients	NULL
could	NULL
not	NULL
be	NULL
attributed	NULL
to	NULL
a	NULL
reduction	NULL
in	NULL
the	NULL
mitogenic	NULL
response	NULL
,	NULL
since	NULL
the	NULL
rate	NULL
of	NULL
thymidine	NULL
incorporation	NULL
for	NULL
cell	NULL
preparations	NULL
from	NULL
patients	NULL
is	NULL
similar	NULL
to	NULL
the	NULL
rate	NULL
for	NULL
normal	NULL
donors	NULL
(	NULL
Table	NULL
II	NULL
)	NULL
.	NULL

It	NULL
should	NULL
be	NULL
noted	NULL
that	NULL
although	NULL
the	NULL
extent	NULL
of	NULL
inhibition	NULL
by	NULL
1,25	NULL
(	NULL
OH	NULL
)	NULL
;	NULL
D	NULL
;	NULL
is	NULL
remarkably	NULL
similar	NULL
among	NULL
different	NULL
individuals	NULL
(	NULL
41-47	NULL
%	NULL
)	NULL
,	NULL
the	NULL
Table	NULL
II	NULL
.	NULL

Effect	NULL
of	NULL
1,25	NULL
(	NULL
OH	NULL
)	NULL
;	NULL
D	NULL
;	NULL
on	NULL
Thymidine	NULL
Incorporation	NULL
into	NULL
PHA-stimulated	NULL
Mononuclear	NULL
Cells	NULL
from	NULL
Normal	NULL
Donors	NULL
and	NULL
DDII	NULL
Patients	NULL
,	NULL
and	NULL
Binding	NULL
of	NULL
|PH	NULL
]	NULL
1,25	NULL
(	NULL
OH	NULL
)	NULL
;	NULL
D	NULL
;	NULL
to	NULL
Cytosol	NULL
Preparations	NULL
from	NULL
the	NULL
Same	NULL
Cells*	NULL
[	NULL
PH	NULL
]	NULL
Thymidine	NULL
incorporation	NULL
PH	NULL
]	NULL
1,25	NULL
(	NULL
OH	NULL
)	NULL
;	NULL
D	NULL
;	NULL
binding	NULL
Donor	NULL
PHA	NULL
PHA	NULL
+	NULL
1,25	NULL
(	NULL
OH	NULL
)	NULL
;	NULL
D	NULL
;	NULL
(	NULL
specific§	NULL
)	NULL
cpm	NULL
cpm	NULL
fmol/mg	NULL
protein	NULL
Experiment	NULL
1	NULL
Patient	NULL
la	NULL
110,200+10,500	NULL
155,800+3,000	NULL
(	NULL
141	NULL
)	NULL
t	NULL
NS	NULL
!	NULL

Normal	NULL
la	NULL
83,800+9,400	NULL
49,600+7,100	NULL
(	NULL
59	NULL
)	NULL
84.3	NULL
Experiment	NULL
2	NULL
Patient	NULL
2	NULL
100,300+1	NULL
1,000	NULL
111,000+3,100	NULL
(	NULL
111	NULL
)	NULL
NS	NULL
Normal	NULL
2	NULL
130,600+5,400	NULL
70,500+5,900	NULL
(	NULL
54	NULL
)	NULL
39.5	NULL
Experiment	NULL
3	NULL
Patient	NULL
3a	NULL
110,200+8,500	NULL
108,600+12,500	NULL
(	NULL
99	NULL
)	NULL
NS	NULL
Patient	NULL
3b	NULL
105,700+6,000	NULL
113,700+13,300	NULL
(	NULL
108	NULL
)	NULL
NS	NULL
Normal	NULL
3	NULL
82,500+8,300	NULL
43,900+1,300	NULL
(	NULL
53	NULL
)	NULL
119.6	NULL
Experiment	NULL
4	NULL
Patient	NULL
4	NULL
134,900+11,300	NULL
144,800+11,200	NULL
(	NULL
107	NULL
)	NULL
63.8	NULL
Normal	NULL
4b	NULL
53,500+4,000	NULL
14,800+2,400	NULL
(	NULL
28	NULL
)	NULL
30.8	NULL
*	NULL
The	NULL
mononuclear	NULL
cells	NULL
in	NULL
the	NULL
experiments	NULL
are	NULL
those	NULL
used	NULL
in	NULL
the	NULL
corresponding	NULL
experiments	NULL
described	NULL
in	NULL
Fig	NULL
.	NULL

1	NULL
and	NULL
Table	NULL
I	NULL
.	NULL

The	NULL
concentration	NULL
of	NULL
1,25	NULL
(	NULL
OH	NULL
)	NULL
;	NULL
D	NULL
;	NULL
was	NULL
10	NULL
nM	NULL
.	NULL

Data	NULL
are	NULL
presented	NULL
as	NULL
the	NULL
mean+SD	NULL
of	NULL
triplicate	NULL
cultures	NULL
.	NULL

The	NULL
inhibition	NULL
of	NULL
thymidine	NULL
incorporation	NULL
into	NULL
lymphocytes	NULL
from	NULL
normal	NULL
donors	NULL
is	NULL
statistically	NULL
significant	NULL
(	NULL
P	NULL
<	NULL
0.01	NULL
)	NULL
.	NULL

The	NULL
enhancement	NULL
of	NULL
thymidine	NULL
incorporation	NULL
into	NULL
lymphocytes	NULL
from	NULL
DDII	NULL
patients	NULL
was	NULL
not	NULL
statistically	NULL
significant	NULL
,	NULL
except	NULL
for	NULL
patient	NULL
la	NULL
(	NULL
P	NULL
<	NULL
0.01	NULL
)	NULL
.	NULL
}	NULL

Numbers	NULL
in	NULL
parentheses	NULL
are	NULL
the	NULL
values	NULL
of	NULL
thymidine	NULL
incorporation	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
1,25	NULL
(	NULL
OH	NULL
)	NULL
;	NULL
D	NULL
;	NULL
,	NULL
expressed	NULL
as	NULL
percents	NULL
of	NULL
the	NULL
control	NULL
values	NULL
.	NULL

§	NULL
Specific	NULL
binding	NULL
was	NULL
obtained	NULL
by	NULL
substracting	NULL
nonspecific	NULL
binding	NULL
from	NULL
total	NULL
binding	NULL
.	NULL

_	NULL
``	NULL
NS	NULL
,	NULL
nonsignificant	NULL
specific	NULL
binding	NULL
.	NULL

NS	NULL
was	NULL
defined	NULL
whenever	NULL
the	NULL
total	NULL
binding	NULL
was	NULL
less	NULL
than	NULL
the	NULL
nonspecific	NULL
binding	NULL
,	NULL
or	NULL
when	NULL
the	NULL
specific	NULL
binding	NULL
was	NULL
<	NULL
50	NULL
%	NULL
of	NULL
the	NULL
nonspecific	NULL
binding	NULL
.	NULL

Nonspecific	NULL
binding	NULL
was	NULL
always	NULL
~100	NULL
cpm	NULL
and	NULL
never	NULL
exceeded	NULL
10	NULL
%	NULL
of	NULL
the	NULL
total	NULL
binding	NULL
in	NULL
normal	NULL
donors	NULL
.	NULL

2014	NULL
-	NULL
Koren	NULL
,	NULL
Ravid	NULL
,	NULL
Liberman	NULL
,	NULL
Hochberg	NULL
,	NULL
Weisman	NULL
,	NULL
and	NULL
Novogrodsky	NULL
number	NULL
of	NULL
binding	NULL
sites	NULL
for	NULL
[	NULL
°H	NULL
]	NULL
1,25	NULL
(	NULL
OH	NULL
)	NULL
;	NULL
D	NULL
;	NULL
in	NULL
parallel	NULL
cultures	NULL
varies	NULL
considerably	NULL
(	NULL
30.8-119.6	NULL
fmol/mg	NULL
protein	NULL
)	NULL
.	NULL

This	NULL
variability	NULL
may	NULL
be	NULL
the	NULL
result	NULL
of	NULL
the	NULL
presence	NULL
of	NULL
monocytes	NULL
and	NULL
other	NULL
non-T	NULL
cell	NULL
types	NULL
.	NULL

Discussion	NULL
Recent	NULL
studies	NULL
suggest	NULL
that	NULL
the	NULL
inhibition	NULL
of	NULL
lymphocyte	NULL
proliferation	NULL
by	NULL
1,25	NULL
(	NULL
OH	NULL
)	NULL
;	NULL
D	NULL
;	NULL
is	NULL
mediated	NULL
by	NULL
a	NULL
specific	NULL
high-affinity	NULL
receptor	NULL
.	NULL

This	NULL
assumption	NULL
is	NULL
based	NULL
mainly	NULL
on	NULL
indirect	NULL
evidence	NULL
:	NULL
the	NULL
inhibitory	NULL
dose	NULL
of	NULL
1,25	NULL
(	NULL
OH	NULL
)	NULL
;	NULL
D	NULL
;	NULL
which	NULL
causes	NULL
half	NULL
maximal	NULL
effect	NULL
is	NULL
similar	NULL
to	NULL
the	NULL
dissociation	NULL
constant	NULL
observed	NULL
in	NULL
parallel	NULL
binding	NULL
studies	NULL
(	NULL
~2	NULL
X	NULL
10-'°	NULL
M	NULL
)	NULL
;	NULL
the	NULL
relative	NULL
efficacy	NULL
of	NULL
vitamin	NULL
D	NULL
metabolites	NULL
as	NULL
inhibitors	NULL
is	NULL
similar	NULL
to	NULL
their	NULL
known	NULL
affinity	NULL
for	NULL
the	NULL
receptor	NULL
binding	NULL
site	NULL
(	NULL
7	NULL
)	NULL
and	NULL
,	NULL
finally	NULL
,	NULL
a	NULL
subpopulation	NULL
of	NULL
mouse	NULL
thymocytes	NULL
that	NULL
does	NULL
not	NULL
have	NULL
a	NULL
high	NULL
affinity	NULL
receptor	NULL
is	NULL
insensitive	NULL
to	NULL
inhibition	NULL
(	NULL
8	NULL
)	NULL
.	NULL

Skin	NULL
fibroblasts	NULL
obtained	NULL
from	NULL
the	NULL
patients	NULL
included	NULL
in	NULL
this	NULL
study	NULL
with	NULL
clinical	NULL
evidence	NULL
of	NULL
end-organ	NULL
resistance	NULL
to	NULL
1,25	NULL
(	NULL
OH	NULL
)	NULL
;	NULL
D	NULL
showed	NULL
a	NULL
receptor	NULL
pattern	NULL
similar	NULL
to	NULL
the	NULL
one	NULL
observed	NULL
by	NULL
us	NULL
in	NULL
their	NULL
stimulated	NULL
mononuclear	NULL
cells	NULL
(	NULL
Table	NULL
II	NULL
)	NULL
:	NULL
normal	NULL
for	NULL
patient	NULL
4	NULL
and	NULL
undetectable	NULL
for	NULL
the	NULL
others	NULL
.	NULL

Neither	NULL
of	NULL
these	NULL
patients	NULL
responded	NULL
clinically	NULL
or	NULL
biochemically	NULL
to	NULL
prolonged	NULL
treatment	NULL
with	NULL
high	NULL
doses	NULL
of	NULL
vitamin	NULL
D	NULL
or	NULL
its	NULL
la-hydroxylated	NULL
metabolites	NULL
.	NULL

The	NULL
induction	NULL
of	NULL
25-hydroxyvitamin	NULL
D	NULL
24-hy-droxylase	NULL
by	NULL
1,25	NULL
(	NULL
OH	NULL
)	NULL
;	NULL
D	NULL
;	NULL
in	NULL
cultured	NULL
skin	NULL
fibroblasts	NULL
may	NULL
serve	NULL
as	NULL
a	NULL
biochemical	NULL
marker	NULL
for	NULL
the	NULL
effect	NULL
of	NULL
the	NULL
hormone	NULL
in	NULL
vitro	NULL
.	NULL

No	NULL
induction	NULL
of	NULL
the	NULL
enzyme	NULL
was	NULL
observed	NULL
in	NULL
cultured	NULL
skin	NULL
fibroblasts	NULL
from	NULL
all	NULL
four	NULL
kindreds	NULL
(	NULL
reference	NULL
11	NULL
and	NULL
unpublished	NULL
observation	NULL
)	NULL
.	NULL

We	NULL
show	NULL
here	NULL
that	NULL
1,25	NULL
(	NULL
OH	NULL
)	NULL
;	NULL
D	NULL
;	NULL
fails	NULL
to	NULL
inhibit	NULL
the	NULL
proliferation	NULL
of	NULL
mitogen-stimulated	NULL
lymphocytes	NULL
from	NULL
the	NULL
same	NULL
patients	NULL
that	NULL
have	NULL
defective	NULL
effector	NULL
systems	NULL
for	NULL
the	NULL
hormone	NULL
,	NULL
including	NULL
the	NULL
patient	NULL
with	NULL
normal	NULL
binding	NULL
.	NULL

This	NULL
finding	NULL
strongly	NULL
supports	NULL
the	NULL
conclusion	NULL
that	NULL
the	NULL
receptor	NULL
for	NULL
1,25	NULL
(	NULL
OH	NULL
)	NULL
;	NULL
D	NULL
;	NULL
mediates	NULL
the	NULL
inhibitory	NULL
effect	NULL
of	NULL
the	NULL
hormone	NULL
on	NULL
lymphocyte	NULL
stimulation	NULL
and	NULL
that	NULL
this	NULL
effect	NULL
requires	NULL
the	NULL
presence	NULL
of	NULL
an	NULL
intact	NULL
coupling	NULL
between	NULL
receptor	NULL
binding	NULL
and	NULL
subsequent	NULL
events	NULL
.	NULL

The	NULL
expression	NULL
of	NULL
this	NULL
receptor	NULL
in	NULL
mononuclear	NULL
cells	NULL
is	NULL
probably	NULL
genetically	NULL
controlled	NULL
by	NULL
the	NULL
same	NULL
mechanism	NULL
as	NULL
the	NULL
expression	NULL
of	NULL
receptors	NULL
in	NULL
skin	NULL
fibroblasts	NULL
and	NULL
classical	NULL
target	NULL
organs	NULL
like	NULL
intestine	NULL
and	NULL
kidney	NULL
.	NULL

The	NULL
susceptibility	NULL
of	NULL
mononuclear	NULL
cells	NULL
to	NULL
inhibition	NULL
by	NULL
1,25	NULL
(	NULL
OH	NULL
)	NULL
;	NULL
D	NULL
;	NULL
can	NULL
readily	NULL
be	NULL
used	NULL
to	NULL
diagnose	NULL
patients	NULL
with	NULL
total	NULL
or	NULL
partial	NULL
end-organ	NULL
resistance	NULL
to	NULL
1,25	NULL
(	NULL
OH	NULL
)	NULL
;	NULL
D.	NULL
Peripheral	NULL
blood	NULL
mononuclear	NULL
cells	NULL
provide	NULL
an	NULL
easily	NULL
accessible	NULL
and	NULL
useful	NULL
cellular	NULL
source	NULL
which	NULL
may	NULL
serve	NULL
as	NULL
a	NULL
model	NULL
for	NULL
the	NULL
study	NULL
of	NULL
the	NULL
mechanism	NULL
of	NULL
1,25	NULL
(	NULL
OH	NULL
)	NULL
;	NULL
D	NULL
;	NULL
action	NULL
under	NULL
physiological	NULL
and	NULL
pathological	NULL
con-ditions	NULL
.	NULL

Resistance	NULL
to	NULL
1,25-Dihydroxyvitamin	NULL
D	NULL
;	NULL
and	NULL
Lymphocyte	NULL
Mitogenesis	NULL
Acknowledgments	NULL
We	NULL
wish	NULL
to	NULL
thank	NULL
Ms.	NULL
C.	NULL
Rotem	NULL
for	NULL
her	NULL
competent	NULL
assistance	NULL
and	NULL
Dr.	NULL
Z.	NULL
Keinan	NULL
for	NULL
his	NULL
help	NULL
in	NULL
the	NULL
course	NULL
of	NULL
this	NULL
work	NULL
.	NULL

References	NULL
1	NULL
.	NULL

Grody	NULL
,	NULL
W.	NULL
W.	NULL
,	NULL
W.	NULL
T.	NULL
Schrader	NULL
,	NULL
and	NULL
B.	NULL
W.	NULL
O'Malley	NULL
.	NULL

1982	NULL
.	NULL

Ac-tivation	NULL
,	NULL
transformation	NULL
of	NULL
subunit	NULL
structure	NULL
and	NULL
steroid	NULL
hormone	NULL
receptors	NULL
.	NULL

Endocrinol	NULL
.	NULL

Rev	NULL
.	NULL

3:141-163	NULL
.	NULL

2	NULL
.	NULL

DeLuca	NULL
,	NULL
H.	NULL
F.	NULL
1981	NULL
.	NULL

Subcellular	NULL
mechanisms	NULL
involving	NULL
vitamin	NULL
D.	NULL
Subcell	NULL
.	NULL

Biochem	NULL
.	NULL

§:251-272	NULL
.	NULL

3	NULL
.	NULL

Norman	NULL
,	NULL
A.	NULL
W.	NULL
,	NULL
J.	NULL
Roth	NULL
,	NULL
and	NULL
L.	NULL
Orci	NULL
.	NULL

1982	NULL
.	NULL

The	NULL
vitamin	NULL
D	NULL
endocrine	NULL
system	NULL
:	NULL
steroid	NULL
metabolism	NULL
,	NULL
hormone	NULL
receptors	NULL
and	NULL
biological	NULL
response	NULL
.	NULL

Endocrinol	NULL
.	NULL

Rev	NULL
.	NULL

3:331-366	NULL
.	NULL

4	NULL
.	NULL

Manolagas	NULL
,	NULL
S.	NULL
C.	NULL
,	NULL
and	NULL
L.	NULL
J.	NULL
Deftos	NULL
.	NULL

1984	NULL
.	NULL

The	NULL
Vitamin	NULL
D	NULL
endocrine	NULL
system	NULL
and	NULL
the	NULL
hematolymphopoietic	NULL
tissue	NULL
.	NULL

Ann	NULL
.	NULL

Intern	NULL
.	NULL

Med	NULL
.	NULL

100:144-146	NULL
.	NULL

5	NULL
.	NULL

Provvedini	NULL
,	NULL
D.	NULL
M.	NULL
,	NULL
C.	NULL
D.	NULL
Tsoukas	NULL
,	NULL
L.	NULL
J.	NULL
Deftos	NULL
,	NULL
and	NULL
S.	NULL
C.	NULL
Manolagas	NULL
.	NULL

1983	NULL
.	NULL

1,25-Dihydroxyvitamin	NULL
D	NULL
;	NULL
receptors	NULL
in	NULL
human	NULL
leukocytes	NULL
.	NULL

Science	NULL
(	NULL
Wash.	NULL
DC	NULL
)	NULL
.	NULL

221:1	NULL
181-1183	NULL
.	NULL

6	NULL
.	NULL

Bhalla	NULL
,	NULL
A.	NULL
K.	NULL
,	NULL
E.	NULL
P.	NULL
Amento	NULL
,	NULL
T.	NULL
L.	NULL
Clemens	NULL
,	NULL
M.	NULL
F.	NULL
Holick	NULL
,	NULL
and	NULL
S.	NULL
M.	NULL
Krane	NULL
.	NULL

1983	NULL
.	NULL

Specific	NULL
high-affinity	NULL
receptors	NULL
for	NULL
1,25-dihydroxyvitamin	NULL
D	NULL
;	NULL
in	NULL
human	NULL
peripheral	NULL
blood	NULL
mononuclear	NULL
cells	NULL
:	NULL
presence	NULL
in	NULL
monocytes	NULL
and	NULL
induction	NULL
in	NULL
T	NULL
lymphocytes	NULL
following	NULL
activation	NULL
.	NULL

J.	NULL
Clin	NULL
.	NULL

Endocrinol	NULL
.	NULL

Metab	NULL
.	NULL

57:1308-1310	NULL
.	NULL

7	NULL
.	NULL

Tsoukas	NULL
,	NULL
C.	NULL
D.	NULL
,	NULL
D.	NULL
M.	NULL
Provvedini	NULL
,	NULL
and	NULL
S.	NULL
C.	NULL
Manolagas	NULL
.	NULL

1984	NULL
.	NULL

1,25-Dihydroxyvitamin	NULL
D	NULL
;	NULL
:	NULL
a	NULL
novel	NULL
immunoregulatory	NULL
hormone	NULL
.	NULL

Science	NULL
(	NULL
Wash.	NULL
DC	NULL
)	NULL
.	NULL

224:1438-1440	NULL
.	NULL

8	NULL
.	NULL

Ravid	NULL
,	NULL
A.	NULL
,	NULL
R.	NULL
Koren	NULL
,	NULL
A.	NULL
Novogrodsky	NULL
,	NULL
and	NULL
U	NULL
.	NULL

A.	NULL
Liberman	NULL
.	NULL

1984	NULL
.	NULL

1,25-Dihydroxyvitamin	NULL
D	NULL
;	NULL
inhibits	NULL
selectively	NULL
the	NULL
mitogenic	NULL
stimulation	NULL
of	NULL
mouse	NULL
medullary	NULL
thymocytes	NULL
.	NULL

Biochem	NULL
.	NULL

Biophys	NULL
.	NULL

Res	NULL
.	NULL

Commun	NULL
.	NULL

123	NULL
;	NULL
163-169	NULL
.	NULL

9	NULL
.	NULL

Feldman	NULL
,	NULL
D.	NULL
,	NULL
T.	NULL
Chen	NULL
,	NULL
M.	NULL
Hirst	NULL
,	NULL
K.	NULL
Colston	NULL
,	NULL
K.	NULL
Karsek	NULL
,	NULL
and	NULL
C.	NULL
Cone	NULL
.	NULL

1980	NULL
.	NULL

Demonstration	NULL
of	NULL
1,25-dihydroxyvitamin	NULL
D	NULL
;	NULL
receptors	NULL
in	NULL
human	NULL
skin	NULL
biopsies	NULL
.	NULL

J.	NULL
Clin	NULL
.	NULL

Endocrinol	NULL
.	NULL

Metab	NULL
.	NULL

51:1463-1465	NULL
.	NULL

10	NULL
.	NULL

Liberman	NULL
,	NULL
U	NULL
.	NULL

A.	NULL
,	NULL
C.	NULL
Eil	NULL
,	NULL
and	NULL
S.	NULL
J.	NULL
Marx	NULL
.	NULL

1983	NULL
.	NULL

Resistance	NULL
to	NULL
1,25-dihydroxyvitamin	NULL
D.	NULL
Association	NULL
with	NULL
heterogeneous	NULL
defects	NULL
in	NULL
cultured	NULL
skin	NULL
fibroblasts	NULL
.	NULL

J.	NULL
Clin	NULL
.	NULL

Invest	NULL
.	NULL

71:192-199	NULL
.	NULL

11	NULL
.	NULL

Chen	NULL
,	NULL
T.	NULL
L.	NULL
,	NULL
M.	NULL
A.	NULL
Hirst	NULL
,	NULL
C.	NULL
M.	NULL
Cone	NULL
,	NULL
Z.	NULL
Hochberg	NULL
,	NULL
H.	NULL
U.	NULL
Tietze	NULL
,	NULL
and	NULL
D.	NULL
Feldman	NULL
.	NULL

1984	NULL
.	NULL

1,25-Dihydroxyvitamin	NULL
D	NULL
resistance	NULL
,	NULL
rickets	NULL
and	NULL
alopecia	NULL
:	NULL
analysis	NULL
of	NULL
receptors	NULL
and	NULL
bioresponse	NULL
in	NULL
cultured	NULL
fibroblasts	NULL
from	NULL
patients	NULL
and	NULL
parents	NULL
.	NULL

J.	NULL
Clin	NULL
.	NULL

Endocrinol	NULL
.	NULL

Metab	NULL
.	NULL

59:383-388	NULL
.	NULL

12	NULL
.	NULL

Liberman	NULL
,	NULL
U	NULL
.	NULL

A.	NULL
,	NULL
R.	NULL
Samuel	NULL
,	NULL
A.	NULL
Halabe	NULL
,	NULL
R.	NULL
Kauli	NULL
,	NULL
S.	NULL
Edelstein	NULL
,	NULL
Y.	NULL
Weisman	NULL
,	NULL
S.	NULL
E.	NULL
Papapoulos	NULL
,	NULL
T.	NULL
L.	NULL
Clemens	NULL
,	NULL
L.	NULL
J.	NULL
Fraher	NULL
,	NULL
and	NULL
J.	NULL
L.	NULL
H.	NULL
O'Riordan	NULL
.	NULL

1980	NULL
.	NULL

End	NULL
of	NULL
organ	NULL
resistance	NULL
to	NULL
1,25-dihydroxy-cholecalciferol	NULL
.	NULL

Lancet	NULL
.	NULL

i:504-507	NULL
.	NULL

13	NULL
.	NULL

Boyum	NULL
,	NULL
A	NULL
.	NULL

1968	NULL
.	NULL

Separation	NULL
of	NULL
leucocytes	NULL
from	NULL
blood	NULL
and	NULL
bone	NULL
marrow	NULL
.	NULL

Scand	NULL
.	NULL

J.	NULL
Clin	NULL
.	NULL

Lab	NULL
.	NULL

Invest	NULL
.	NULL

24	NULL
(	NULL
Suppl	NULL
)	NULL
:97	NULL
.	NULL

14	NULL
.	NULL

Lowry	NULL
,	NULL
O.	NULL
H.	NULL
,	NULL
N.	NULL
J.	NULL
Rosenbrough	NULL
,	NULL
A.	NULL
L.	NULL
Farr	NULL
,	NULL
and	NULL
R.	NULL
J.	NULL
Randall	NULL
.	NULL

1951	NULL
.	NULL

Protein	NULL
measurements	NULL
with	NULL
the	NULL
Folin	NULL
phenol	NULL
reagent	NULL
.	NULL

J.	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

193:265-275	NULL
.	NULL

2015	NULL

